Skip to main content
Clinical Trials/EUCTR2009-010288-17-SE
EUCTR2009-010288-17-SEActive, not recruitingNot Applicable

Breast cell turnover and mammographic density in women with Polycystic Ovary Syndrome (PCOS) - Breast cell turnover PCOS

Karolinska Hospital0 sitesStarted: March 13, 2009Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
Female

Inclusion Criteria

  • - Healthy control subjects (no chronic illnesses)
  • - Women who have the PCOS- diagnosis according to Rotterdam criteria
  • - At least 18 but not older than 39 years at the time of the study start
  • - No smoking
  • - BMI > 19 and <30 kg/m2
  • - Women who are willing to accept OC-treatment
  • - No contraindications for OC-treatment
  • - If any kind of hormonal contraception, acceptance for a three months wash-out period before entering the study
  • - Willing to give informed consent in writing
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • Presence or history of venous or arterial thrombotic/thromboembolic events(e.g. deep venous thrombosis, pulmonary embolism, myocardial infarction) or of a cerebrovascular accident.
  • The presence of a severe or multiple risk factors for venous or arterial thrombosis such as increasing age; smoking (with heavier smoking and increasing age the risk further increases, especially in women over 35 years of age; a positive family history (i.e. venous or arterial trombormbolism ever in sibling or parent at a relative early age); obesity (BMI > 30 kg/m2) dyslipoproteinaemia; hypertension, migraine, valvular heart disease, arterial fibrillation; prolonged immobilization, major surgery and surgery to the legs, or major trauma until two weeks after full remobilization; systemic lupus erythematosus (SLE), Mb Crohn or ulcerative colitis; sickle cell disease.
  • Hereditary or acquired predisposition for APC-resistance, antitrombin-III deficiency, protein-C deficiency, hyperhomocysteinaemia and antiphospholipid antibodies.
  • Pancreatitis or history ofhypertriglyceridaemia.
  • Presence or history of liver tumors (benign or malignant).
  • Known or suspected sex steroid-influenced malignancies (e.g. of the genital organs or the breasts).
  • Contraindication for antimineralocorticoid medication (conditions that predispose to hyperkalemia).
  • History of migraine with focal neurological symptoms.
  • Diabetes mellitus with vascular involvement.
  • Severe dyslipidemia
  • Severe hypertension.
  • Hepatic dysfunction.
  • Adrenal insufficiency.
  • Undiagnosed vaginal bleeding
  • Known or suspected pregnancy.
  • Before spontaneous menstruation has occurred following a delivery or abortion.
  • Breastfeeding or within 2 months after stopping breastfeeding prior to the start of the study medication.
  • An abnormal cervical smear.
  • Use of an injectable hormonal method of contraception; within 6 months of an inj. with a 3-months duration, within 4 months of an inj. with a 2-month duration, within 2 months of an inj. with a 1-months duration.

Investigators

Sponsor
Karolinska Hospital

Similar Trials